CEA.Tg mice bearing MC32A tumors and treated with the vaccine alone had significantly higher (*P ≤ 0.05) percentages of Ki67+/CD44+ CD4+FoxP3- T cells in the tumor microenvironment (Figure 5F). Here, CEACAM5 is linked to neoplasm.